Search

Objective: To determine the efficiency of our vitrification technique when applied in young fertile women. Design: Clinical research and application. Setting: In vitro fertilization center. Patient(s): Twenty-one women were recruited from the navy community with 19 patients finishing the study. Intervention(s): Vitrified oocytes with use of the electron microscopic grid method were warmed 6 months after vitrification. Surviving metaphase II oocytes were microinjected for fertilization, and clinical results were evaluated. Main Outcome Measure(s): Survival, fertilization, and cleavage rate. Pregnancy and implantation rate. Result(s): Three hundred ninety-five oocytes were warmed, of which 320 oocytes (81.0%) survived. Two hundred eighty-five metaphase II oocytes were microinjected for fertilization; 206 of them (72.3%) fertilized, and 53 embryos were transferred to 19 patients (in 20 warming cycles). Twenty-four of 53 transferred embryos (45.3%) implanted as confirmed by ultrasound examination. Of the 20 transfers, 16 resulted in clinical pregnancy (80%), 3 miscarried (15%), and 13 (65%) went on to produce 20 live births, respectively. This is much higher in comparison with our previous data using supernumerary oocytes where the rates of implantation and pregnancy were 6% and 21%. Live-birth rates per warmed oocyte and per injected oocyte were 5.1% and 7.2%, respectively. Conclusion(s): High pregnancy and implantation rates were observed after 6 months of cryopreservation by vitrification when oocytes from fertile woman were used. Proper screening of candidates for oocyte cryopreservation is of crucial importance to assure a favorable pregnancy outcome. [Copyright &y& Elsevier]

: ObjectiveTo assess the usefulness of the vitrification method in clinical practice.: DesignClinical study of vitrification of human oocytes.: SettingA university-affiliated hospital.: Patient(s)Thirty-four patients who agreed to undergo additional IVF-ET after the failed fresh cycle using the previously vitrified/thawed oocytes.: Intervention(s)Surplus oocytes from the IVF-ET patients were vitrified for the next cycle.: Main outcome measure(s)Morphologic normality of post-thawed oocytes, fertilization, cleavage, pregnancy, and implantation rate.: Result(s)Overall morphological survival and fertilization rates of vitrified/liquefied oocytes were 68.6% (325/474) and 71.7% (142/198), respectively. Pregnancy rate and implantation rate per embryo transfer were 21.4% (6/28) and 6.4% (8/125), respectively. All pregnancies resulted in the delivery of healthy babies (1 twin and 5 singletons/6 pregnancies).: Conclusion(s)The feasibility of the vitrification method for human oocytes was confirmed by our clinical results. Subsequent studies on vitrification and thawing procedures should be undertaken for further optimizing the vitrification method. [Copyright &y& Elsevier]

Nozzle wear dependence on abrasive water jet system parameters and nozzle geometry is experimentally investigated. Experimental procedures for evaluating long term and accelerated nozzle wear are discussed. Accelerated wear tests are conducted to study the effects of nozzle length, inlet angle, diameter, orifice diameter, abrasive flow rate, and water pressure on wear. An empirical model for nozzle weight loss rate is developed and is shown to correlate well with experimental measurements. [Copyright &y& Elsevier]

Objective: To determine the predictive value of an aneuploid diagnosis with a targeted next-generation sequencing-based preimplantation genetic testing for aneuploidy (PGT-A) assay in prognosticating the failure of a successful delivery.Design: Prospective, blinded, multicenter, nonselection study. All usable blastocysts were biopsied, and the single best morphologic blastocyst was transferred before genetic analysis. Preimplantation genetic testing for aneuploidy was performed after clinical outcome was determined. Clinical outcomes were compared to PGT-A results to calculate the predictive value of a PGT-A aneuploid diagnosis.Setting: Fertility centers.Patient(s): Couples undergoing their first in vitro fertilization cycle without recurrent pregnancy loss, antral follicle count < 8, or body mass index ≥ 35 kg/m2.Intervention(s): None.Main Outcome Measure(s): The primary outcome was the ability of the analytical result of aneuploid to predict failure to deliver (clinical result). A secondary outcome was the impact of the trophectoderm biopsy on sustained implantation.Result(s): Four hundred two patients underwent 484 single, frozen, blastocyst transfers. The PGT-A aneuploid diagnosis clinical error rate was 0%. There was no difference in sustained implantation between the study group and an age-matched control group, where biopsy was not performed (47.9% vs. 45.8).Conclusion(s): The PGT-A assay evaluated was highly prognostic of failure to deliver when an aneuploid result was obtained. Additionally, the trophectoderm biopsy had no detectable adverse impact on sustained implantation.Clinical Trial Registration Numbers: NCT02032264 and NCT03604107. [ABSTRACT FROM AUTHOR]

Objective To determine whether endometrial hCG infusion at the time of human blastocyst transfer impacts implantation rates. Design Randomized double-blinded placebo-controlled trial. Setting Academic. Patient(s) Infertile couples with the female partner less than 43 years old (n = 300) undergoing fresh or frozen ET of one or two blastocysts. Intervention(s) Patients undergoing ET were randomized into either a treatment or a control group. The treatment group received an infusion of 500 IU of hCG diluted in ET media. The control group received a sham infusion of ET media. Infusions were done using a separate catheter less than 3 minutes before actual ET. Main Outcome Measure(s) Sustained implantation rate: ongoing viable gestation (primary outcome) and ongoing pregnancy rate (secondary outcome). Result(s) A total of 473 blastocysts were transferred into 300 patients. There were no differences between the two groups in sustained implantation rate (48.1% in the hCG group, 44.2% in the control group) or ongoing pregnancy rate (58.8% in the hCG group, 52.0% in the control group). Conclusion(s) Endometrial infusion of hCG at the time of blastocyst ET does not improve sustained implantation rates. Clinical Trial Registration Number NCT01643993 . [ABSTRACT FROM AUTHOR]